You are here

bispecific antibodies

Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Fierce Biotech

bispecific antibodies

Flag link:

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Pharmaceutical Business Review

bispecific antibodies

clinical trials

Flag link:

Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call

Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call

Endpoints

bispecific antibodies

Flag link:

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Fierce Biotech

immuno-oncology

bispecific antibodies

Flag link:

FDA draft guidance suggests comparing bispecifics to monospecific antibodies

FDA draft guidance suggests comparing bispecifics to monospecific antibodies

BioCentury

bispecific antibodies

Flag link:

Xencor, Astellas Pharma collaborate on novel bispecific antibody program

Xencor, Astellas Pharma collaborate on novel bispecific antibody program

Pharmaceutical Business Review

bispecific antibodies

Flag link:

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

Endpoints

bispecific antibodies

acute myeloid leukemia

Flag link:

The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance

The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance

Endpoints

bispecific antibodies

Flag link:

In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact

In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact

Fierce Biotech

bispecific antibodies

Flag link:

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

Endpoints

bispecific antibodies

clinical trials

Flag link:

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

Fierce Biotech

bispecific antibodies

Flag link:

GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment

GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment

CP Wire

Go Therapeutics

drug development

bispecific antibodies

Flag link:

Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies

Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies

Med City News

bispecific antibodies

Flag link:

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Endpoints

bispecific antibodies

Flag link:

J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table

J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table

Endpoints

drug development

bispecific antibodies

Flag link:

Amgen, Immatics In Cancer Drug Partnership

Amgen, Immatics In Cancer Drug Partnership

Investopedia

bispecific antibodies

Flag link:

Incyte puts up $200M in bispecifics deal with Merus

Incyte puts up $200M in bispecifics deal with Merus

BioPharma Dive

bispecific antibodies

Flag link:

AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro

AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro

Endpoints

bispecific antibodies

Flag link:

Novartis jumps into bi-specific antibody space with $150 million Xencor deal

Novartis jumps into bi-specific antibody space with $150 million Xencor deal

BioPharma Dive

bispecific antibodies

acute myeloid leukemia

B-cell malignancies

Flag link:

GSK doubles down on Zymeworks’ platform technologies with $908M deal

GSK doubles down on Zymeworks’ platform technologies with $908M deal

Fierce Biotech

bispecific antibodies

drug development

Flag link:

Pages